Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447133 · ClinicalTrials.gov registry record
TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro
A clinical trial, sponsored by Topcon Medical Systems.
- Completed
- Registry status
- 12
- Enrollment target
NCT02447133: Completed study, sponsored by Topcon Medical Systems.
NCT02447133 is a clinical trial that has completed, run by Topcon Medical Systems. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02447133 has completed, sponsored by Topcon Medical Systems.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
Study Summary
The objective of this study is to validate the TopQ cutoff scores, which have been previously determined.
Primary Outcome
To validate the values of the predetermined TopQ score by showing the variability above and below the TopQ score of 25 for 12x9 Wide, 28 for 6x6 Macula, and 30 for 6x6 Disc scans.
Interventions
- DEVICE 3D OCT-1 Maestro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-05 |
What the finished NCT02447133 record still lists
NCT02447133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 3D OCT-1 Maestro is the first listed.
NCT02447133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02447133 about?
NCT02447133 is a clinical study titled "TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro". The objective of this study is to validate the TopQ cutoff scores, which have been previously determined.
What is the current status of trial NCT02447133?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2015-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02447133?
The interventions under investigation include: 3D OCT-1 Maestro (DEVICE).
Who is sponsoring clinical trial NCT02447133?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia